VitroScan
Private Company
Funding information not available
Overview
VitroScan is a private, late-stage diagnostics company leveraging a proprietary ex vivo micro-tumor platform to advance precision oncology. Its core offering is a predictive testing service that uses patient-derived 3D micro-tumors to model treatment responses, aiming to improve clinical outcomes for cancer patients and reduce late-stage failures in drug development. The company has achieved ISO 15189 accreditation for its quality management system and is actively engaged in clinical trials to further validate its platform. With a team of experts in oncology and bioinformatics, VitroScan is positioned at the intersection of diagnostics and translational drug development support.
Technology Platform
Ex vivo micro-tumor platform that preserves native tumor architecture, cellular heterogeneity, and stromal interactions in a 3D matrix to model patient-specific treatment responses and de-risk drug development.
Opportunities
Risk Factors
Competitive Landscape
VitroScan competes in the functional precision oncology and translational research services space. Key competitors include companies developing patient-derived organoid (PDO) platforms (e.g., Crown Bioscience, Hubrecht Organoid Technology), those using patient-derived xenograft (PDX) models, and other ex vivo testing services. Its differentiation lies in its specific focus on preserving the native tumor microenvironment and its direct integration into clinical trial programs for validation.